Over the past 12 months, 3 insiders at Aprea Therapeutics, Inc. filed 4 open-market SEC Form 4 transactions on APRE: 4 purchases worth $61K and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Jan 30, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 30, 26 | Oren GiladPresident/CEO | BUY | 28.1K | $0.89 | $25K |
| Jan 30, 26 | John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | BUY | 5.7K | $0.89 | $5K |
| Dec 10, 25 | Marc DueyDirector | BUY | 21.5K | $1.17 | $25K |
| Dec 10, 25 | John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | BUY | 5.0K | $1.17 | $6K |
| Apr 3, 25 | Oren GiladPresident/CEO | BUY | 3.0K | $1.87 | $6K |
| Oct 23, 24 | Oren GiladPresident/CEO | BUY | 500 | $3.92 | $2K |
| Oct 18, 24 | Marc DueyDirector | SELL | 6.5K | $4.58 | $30K |
| Oct 16, 24 | Marc DueyDirector | BUY | 30.0K | $4.39 | $132K |
| Oct 15, 24 | Oren GiladPresident/CEO | BUY | 250 | $2.90 | $725 |
| Oct 14, 24 | Marc DueyDirector | BUY | 190 | $2.58 | $490 |
| Oct 14, 24 | Oren GiladPresident/CEO | BUY | 1.0K | $2.59 | $3K |
| Oct 11, 24 | John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | BUY | 50 | $2.46 | $123 |
| Oct 11, 24 | Bernd R. SeizingerDirector | BUY | 10.0K | $2.68 | $27K |
| Oct 10, 24 | Oren GiladPresident/CEO | BUY | 150 | $2.54 | $381 |
| Oct 10, 24 | John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | BUY | 450 | $2.61 | $1K |
| Mar 13, 24 | Oren GiladPresident, CEO | BUY | 2.0K | $7.29 | $15K |
| Mar 13, 24 | John B Henneman IIIDirector | BUY | 6.9K | $7.29 | $50K |
| Mar 13, 24 | John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | BUY | 1.0K | $7.29 | $7K |
| Mar 13, 24 | Bernd R. SeizingerDirector | BUY | 6.9K | $7.29 | $50K |
| Jun 7, 23 | Bernd R. SeizingerDirector | BUY | 6.0K | $3.68 | $22K |
| Jun 6, 23 | Bernd R. SeizingerDirector | BUY | 4.1K | $3.63 | $15K |
| May 18, 22 | Christian S SchadeChairman & CEO | BUY | 37.5K | $0.64 | $24K |
| May 18, 22 | Bernd R. SeizingerDirector | BUY | 50.0K | $0.71 | $36K |
| Feb 28, 22 | Eyal C. AttarSVP, Chief Medical Officer | SELL | 36.0K | $1.73 | $62K |
| Dec 1, 21 | Gregory Alan KorbelSVP, Chief Business Officer | SELL | 27.5K | $3.96 | $109K |
| Nov 1, 21 | Gregory Alan KorbelSVP, Chief Business Officer | SELL | 27.5K | $5.00 | $138K |
| Oct 1, 21 | Lars B. AbrahmsenSVP, Chief Scientific Officer | SELL | 50.0K | $4.89 | $245K |
| Oct 1, 21 | Gregory Alan KorbelSVP, Chief Business Officer | SELL | 27.5K | $4.89 | $134K |
| Sep 20, 21 | Lars B. AbrahmsenSVP, Chief Scientific Officer | SELL | 25.0K | $4.97 | $124K |
| Sep 20, 21 | Gregory Alan KorbelSVP, Chief Business Officer | SELL | 27.5K | $4.98 | $137K |
| Sep 16, 21 | Eyal C. AttarSVP, Chief Medical Officer | SELL | 16.0K | $4.68 | $75K |
Over the past 12 months, insiders at Aprea Therapeutics, Inc. filed 4 open-market purchases worth $61K and 0 sales worth $0 on APRE, which makes them net buyers over the period. The most recent Form 4 was filed on Jan 30, 26.
The largest recent open-market APRE insider purchase in our data was $132K by Marc Duey, Director, filed on Oct 16, 24.
3 different insiders at Aprea Therapeutics, Inc. filed open-market SEC Form 4 transactions on APRE over the last 12 months.
InsiderTape plots every APRE insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Aprea Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →